COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,050 Articles (22,627 medRxiv, 8,423 bioRxiv)

Most recent first Previous |  Page 1712: Articles 17111-17120  | Next

Single-Arm, Open-Label Phase 2 Trial of Preemptive Methylprednisolone to Avert Progression to Respiratory Failure in High-Risk Patients with COVID-19
Cabanillas, F., Morales, J., Conde, J. G., Bertran-Pasarell, J., Fernandez, R., Hernandez-Silva, Y., Liboy, I., Bryan-Diaz, J., Arraut-Gonzalez, J.
10.1101/2021.03.08.21253117 — Posted: 2021-03-09
SARS-COV-2 antibody prevalence in patients on dialysis in the US in January 2021
Anand, S., Montez-Rath, M., Han, J., Cadden, L., Hunsader, P., Kerschmann, R., Beyer, P., Boyd, S. D., Garcia, P., Dittrich, M., Block, G. A., Parsonnet, J., Chertow, G. M.
10.1101/2021.03.07.21252786 — Posted: 2021-03-09
The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD
Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreno, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., Rijnink, W., Alshammary, H., Borcherding, N., Gonzalez Reiche, A., Srivastava, K., Sordillo, E. M., van Bakel, H., Turner, J. S., Bajic, G., Simon, V. M., Ellebedy, A. H., Krammer, F.
10.1101/2021.03.07.21253098 — Posted: 2021-03-09 Discussion: Onsite
A general computational framework for COVID-19 modelling, with applications to testing varied interventions in education environments
Moore, J. W., Lau, Z., Kaouri, K., Dale, T. C., Woolley, T. E.
10.1101/2021.03.08.21253122 — Posted: 2021-03-09
Predicting vaccine hesitancy from area-level indicators: A machine learning approach
Carrieri, V., Lagravinese, R., Resce, G.
10.1101/2021.03.08.21253109 — Posted: 2021-03-09
Effectiveness of a telerehabilitation program for COVID-19 survivors (TERECO) on exercise capacity, pulmonary function, lower limb muscle strength, and quality of life: a randomised controlled trial
Li, J., Xia, W., Zhan, C., Liu, S., Yin, Z., Wang, J., Chong, Y., Zheng, C., Fang, X., Cheng, W., Reinhardt, J. D.
10.1101/2021.03.08.21253007 — Posted: 2021-03-09
A quantitative risk estimation platform for indoor aerosol transmission of COVID-19
Parhizkar, H., Van Den Wymelenberg, K., Haas, C., Corsi, R.
10.1101/2021.03.05.21252990 — Posted: 2021-03-09
Categorizing the Status of COVID-19 Outbreaks Around the World
Callan, J. P., Nouwen, C. J. A., Lexmond, A. S., Fourtassi, O.
10.1101/2021.03.08.21252586 — Posted: 2021-03-09
COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar
Abu-Raddad, L. J., Dargham, S., Chemaitelly, H., Coyle, P. J., Al Kanaani, Z., Al Kuwari, E., Butt, A. A., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., Nasrallah, G. K., YASSINE, H. M., Al Kuwari, M. G., Al Romaihi, H. E., Al-Thani, M. H., Al Khal, A., Bertollini, R.
10.1101/2021.03.06.21252601 — Posted: 2021-03-09
COVID-19 vaccine distrust in Colombian university students: Frequency and associated variables
Campo-Arias, A., Pedrozo-Pupo, J. C.
10.1101/2021.03.07.21253080 — Posted: 2021-03-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).